Veracyte, Inc.
VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$32.21
Price+5.82%
$1.77
1Y
Price
Market Cap
$2.559b
Mid
Price/Earnings 3y Avg5y Avg
39.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+32.7%
EBITDA Margin+29.3%
Net Profit Margin+34.3%
Free Cash Flow Margin+32.7%
EBITDA Margin+29.3%
Net Profit Margin+34.3%
Free Cash Flow MarginRevenue
$517.145m
+16.0%
1y CAGR+20.4%
3y CAGR+24.1%
5y CAGREarnings
$66.353m
+174.9%
1y CAGR+67.9%
3y CAGR+63.9%
5y CAGREPS
$0.82
+164.5%
1y CAGR+65.0%
3y CAGR+62.2%
5y CAGRBook Value
$1.310b
$1.406b
Assets$96.443m
Liabilities$39.654m
DebtDebt to Assets
2.8%
0.5x
Debt to EBITDAFree Cash Flow
$126.630m
+97.6%
1y CAGR+1220.9%
3y CAGR+940.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company